Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRDF

Cardiff Oncology Inc

Sep 12 • 04:00PM ET

2.05

-0.03 -1.44 %

Healthcare • Biotechnology • USA • NASD

Peers: BPMC FOLD XNCR NERV AFMD ONC KPTI TVRD ATNM

| Held by: VTI IWM VXF VTWO IWN IWO VFMO IWC RSSL VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.88	Insider Own	8.19%	Shs Outstand	66.53M	Perf Week	-5.53%
Market Cap	136.38M	Forward P/E	-	EPS next Y	-0.87	Insider Trans	5.62%	Shs Float	61.07M	Perf Month	-16.33%
Enterprise Value	66.61M	PEG	-	EPS next Q	-0.20	Inst Own	37.77%	Short Float	26.05%	Perf Quarter	-45.91%
Income	-51.04M	P/S	247.96	EPS this Y	12.11%	Inst Trans	-10.99%	Short Ratio	8.38	Perf Half Y	-48.10%
Sales	0.55M	P/B	2.33	EPS next Y	-3.89%	ROA	-71.96%	Short Interest	15.91M	Perf YTD	-52.76%
Book/sh	0.88	P/C	1.92	EPS next 5Y	-4.08%	ROE	-91.93%	52W High	5.64 -63.65%	Perf Year	-10.48%
Cash/sh	1.07	P/FCF	-	EPS past 3/5Y	-9.55% 19.36%	ROIC	-86.41%	52W Low	1.90 7.89%	Perf 3Y	-27.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	23.91% 22.80%	Gross Margin	-19.78%	Volatility	4.49% 5.59%	Perf 5Y	-66.34%
Dividend TTM	-	EV/Sales	121.11	EPS Y/Y TTM	3.93%	Oper. Margin	-9950.92%	ATR (14)	0.15	Perf 10Y	-99.52%
Dividend Ex-Date	-	Quick Ratio	4.42	Sales Y/Y TTM	-17.89%	Profit Margin	-9348.53%	RSI (14)	36.50	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	4.42	EPS Q/Q	20.24%	SMA20	-5.83%	Beta	1.63	Target Price	10.42
Payout	-	Debt/Eq	0.02	Sales Q/Q	-25.77%	SMA50	-29.36%	Rel Volume	0.32	Prev Close	2.08
Employees	33	LT Debt/Eq	0.01	Earnings	Jul 29 AMC	SMA200	-38.66%	Avg Volume	1.90M	Price	2.05
IPO	Jul 27, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.09% 10.60%	Trades		Volume	613,235	Change	-1.44%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$19
Jun-24-25	Initiated	Jefferies	Hold	$3.50
Sep-06-24	Initiated	Craig Hallum	Buy	$8
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform	$19
Aug-09-21	Resumed	Maxim Group	Buy	$30 → $20
Oct-22-20	Initiated	H.C. Wainwright	Buy	$27
Oct-08-20	Initiated	Piper Sandler	Overweight	$25

Aug-28-25 04:05PM	Cardiff Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Jul-29-25 05:25PM	Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -11.26% -24.77%
04:23PM	Cardiff Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:07PM	Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) (GlobeNewswire)
04:05PM	Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update (GlobeNewswire)
09:25AM	Loading…
Jun-19-25 09:25AM	Cardiff Oncology to share CRDF-004 trial data on July 29 (TipRanks)
09:25AM	Cardiff selloff brings attractive entry point, says H.C. Wainwright (TipRanks)
Jun-17-25 04:05PM	Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC (GlobeNewswire) -18.38%
Jun-02-25 04:05PM	Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 (GlobeNewswire)
May-14-25 12:00PM	Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know (Zacks)
May-08-25 05:25PM	Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.62%
04:05PM	Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update (GlobeNewswire)
May-02-25 03:35AM	Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon (Seeking Alpha)
Apr-28-25 10:00AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-24-25 10:01AM	Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
04:05PM	Loading…
Apr-23-25 04:05PM	Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naive Patients (GlobeNewswire)
04:05PM	Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Na ve Patients (GlobeNewswire)
Apr-15-25 04:10PM	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.38%
04:05PM	Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer (GlobeNewswire)
Mar-26-25 03:57PM	Is Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5? (InsiderMonkey) -6.84%
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Feb-27-25 04:05PM	Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update (GlobeNewswire) -8.97%
Feb-26-25 08:12AM	Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com) +5.44%
Feb-24-25 04:05PM	Cardiff Oncology to Present at Upcoming Investor Conferences (GlobeNewswire) -7.24%
Feb-20-25 04:05PM	Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update (GlobeNewswire)
Dec-26-24 09:00AM	Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook (GlobeNewswire) +10.71%
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) -5.12%
Dec-18-24 11:12AM	Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments (PR Newswire) -16.07%
Dec-14-24 06:50AM	Cardiff Oncology price target raised to $10 from $7 at Piper Sandler (TipRanks)
Dec-11-24 07:19AM	Cardiff Oncology Reports Promising Phase 2 Trial Results (TipRanks)
07:20AM	Loading…
Dec-10-24 07:20AM	Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering (GlobeNewswire) +54.92%
06:00AM	Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial (GlobeNewswire)
Nov-19-24 08:00AM	Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC (GlobeNewswire)
Nov-07-24 04:05PM	Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update (GlobeNewswire) +7.35% -24.69%
Oct-30-24 04:30PM	Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC (GlobeNewswire)
Aug-08-24 04:05PM	Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update (GlobeNewswire) +11.74%
Aug-01-24 04:05PM	Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update (GlobeNewswire)
May-29-24 04:05PM	Cardiff Oncology to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-13-24 04:05PM	Cardiff Oncology to Present at Upcoming Investor Conferences in May (GlobeNewswire)
May-09-24 12:15PM	Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 (PR Newswire) +5.62%
May-07-24 06:00AM	The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028 (InvestorPlace)
May-02-24 09:54PM	CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.91% -21.43%
05:45PM	Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update (GlobeNewswire)
Apr-25-24 04:05PM	Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update (GlobeNewswire)
Apr-08-24 04:05PM	Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study (GlobeNewswire)
Apr-01-24 08:50AM	Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) +7.30%
Mar-21-24 07:55AM	Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why (Zacks)
Mar-14-24 08:50AM	Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going (Zacks)
08:08AM	Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last? (Zacks)
Mar-06-24 04:05PM	Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 (GlobeNewswire) +6.58% -9.77%
12:00PM	What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now? (Zacks)
Mar-01-24 10:12AM	Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com) +64.87%
Feb-29-24 07:40PM	Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update (GlobeNewswire)
04:06PM	Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC (GlobeNewswire)
04:05PM	Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) (GlobeNewswire)
Feb-26-24 08:00AM	Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-22-24 08:00AM	Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update (GlobeNewswire)
Jan-17-24 10:30AM	Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research (PR Newswire) -9.82%
Nov-20-23 04:05PM	Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference (PR Newswire)
Nov-02-23 04:05PM	Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update (PR Newswire) +8.57%
Oct-26-23 04:05PM	Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update (PR Newswire)
Oct-23-23 08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire) -10.27%
Oct-11-23 09:35AM	Cardiff Oncology (CRDF) Loses -29.75% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-26-23 04:05PM	Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy (PR Newswire)
Sep-05-23 08:00AM	Cardiff Oncology to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-09-23 04:05PM	Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update (PR Newswire) -12.39% +8.38%
Aug-07-23 04:05PM	Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship (PR Newswire) -8.19% +38.85%
Jul-24-23 05:09PM	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-20-23 05:22PM	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-05-23 08:00AM	Cardiff Oncology to Present at the Jefferies Healthcare Conference (PR Newswire)
May-04-23 04:10PM	Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update (PR Newswire)
Mar-28-23 08:00AM	Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer (PR Newswire)
Mar-06-23 08:15AM	Cardiff Oncology Formally Introduces Scientific Advisory Board (PR Newswire)
Mar-04-23 07:11AM	Cardiff Oncology Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-02-23 04:10PM	Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update (PR Newswire)
Feb-27-23 08:15AM	Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference (PR Newswire)
Feb-02-23 08:00AM	Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer (PR Newswire)
Jan-10-23 08:00AM	Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference (PR Newswire)
Nov-21-22 10:52AM	Cardiff Oncology to Present at Upcoming Investor Conferences (PR Newswire)
Nov-08-22 08:15AM	Cardiff Oncology to Present at the Jefferies London Healthcare Conference (PR Newswire)
Nov-03-22 04:10PM	Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates (PR Newswire)
Sep-12-22 04:05PM	Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates (PR Newswire) +10.69% -41.12%
Sep-10-22 07:30AM	Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022 (PR Newswire)
Sep-08-22 08:15AM	Cardiff Oncology to Present at Upcoming Investor Conferences in September (PR Newswire)
Sep-06-22 08:00AM	Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022 (PR Newswire) -9.25%
Aug-29-22 08:00AM	Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022 (PR Newswire) -5.73%
Aug-04-22 04:10PM	Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates (PR Newswire) +10.00%
Jul-05-22 08:30AM	Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022 (PR Newswire) +13.73%
Jul-02-22 09:10AM	Is Cardiff Oncology, Inc. (NASDAQ:CRDF) Popular Amongst Institutions? (Simply Wall St.)
May-17-22 08:30AM	Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference (PR Newswire) +6.06%
May-09-22 08:02AM	Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation (Simply Wall St.) -6.06%
May-05-22 04:10PM	Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates (PR Newswire) -6.29%
Apr-12-22 04:00PM	Cardiff Oncology Announces Departure of Chief Medical Officer (PR Newswire)
Apr-08-22 01:05PM	Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting (PR Newswire)
01:05PM	Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models (PR Newswire)
Mar-22-22 09:05AM	Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC (PR Newswire) +7.56%
Mar-17-22 06:32AM	Cardiff Oncology, Inc. (NASDAQ:CRDF) insiders placed bullish bets worth US$681k in the last 12 months (Simply Wall St.) +6.48%
Mar-08-22 04:45PM	Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting (PR Newswire) +7.76%

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PACE GARY W	Director	Jul 30 '25	Buy	2.45	275,000	673,750	1,330,676	Jul 31 04:05 PM
PACE GARY W	Director	Jul 30 '25	Buy	2.45	15,000	36,750	1,345,676	Jul 31 04:05 PM
Levine James E.	Chief Financial Officer	Dec 17 '24	Buy	5.42	2,752	14,905	65,316	Dec 18 04:37 PM
Levine James E.	Chief Financial Officer	Dec 18 '24	Buy	5.00	2,400	12,000	67,716	Dec 18 04:37 PM
Levine James E.	Chief Financial Officer	Dec 16 '24	Buy	3.83	2,564	9,820	62,564	Dec 18 04:37 PM
TANNENBAUM RENEE P	Director	Dec 12 '24	Buy	3.42	10,000	34,224	20,000	Dec 16 05:00 PM
PACE GARY W	Director	Dec 11 '24	Buy	2.60	350,115	910,299	1,047,876	Dec 12 04:05 PM
PACE GARY W	Director	Dec 11 '24	Buy	2.60	11,500	29,900	1,059,376	Dec 12 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRDF

Cardiff Oncology Inc

Upgrade your FINVIZ experience